Adherence to a Mediterranean diet may improve serum adiponectin in adults with nonalcoholic fatty liver disease: The MEDINA randomized controlled trial

• DOI: 10.1016/j.nutres.2023.09.005
• Publication Date: 2023-09-12T06:16:48Z
• Authors: Anjana Reddy; Paul Della Gatta; Shaun Mason; Amanda J. Nicoll; Marno Ryan; Catherine Itsiopo...; Gavin Abbott; Nathan A. Johnson; Siddharth Sood; Stuart K. Roberts; Elena S. George; Audrey C. Tierney
• Keywords: Mediterranean Diet; Resistin

Nonalcoholic fatty liver disease (NAFLD) affects approximately 30% of adults worldwide, with chronic low-grade inflammation being a key pathophysiological feature progression. The Mediterranean diet (MedDiet) is recognized for improving metabolic and hepatic outcomes in people diabetes NAFLD, part, via anti-inflammatory properties. aim this study was to determine the effect an ad libitum MedDiet versus low-fat (LFD) on inflammatory markers NAFLD. It hypothesized that MedDiet, its individual components, would improve inflammation. This multicenter, randomized controlled trial, participants or LFD intervention 12 weeks. Primary included change from baseline weeks serum high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-α, adiponectin, leptin, resistin. Forty-two (60% female; age 52.3 ± 12.6 years; body mass index, 32.2 6.2 kg/m²) were (n = 19) 23). At weeks, showed greater decrease leptin compared (–1.20 3.9 ng/mL vs 0.64 3.5 ng/mL, P .010). Adiponectin significantly improved within (13.7 9.2 µg/mL 17.0 12.5 µg/mL, .016), but not group. No statistically significant changes observed other following LFD. Adherence both arms, although improvements seen intervention, absence weight loss. did elicit markers. High-quality clinical trials appropriately powered are required population.